Is Testosterone Therapy Safe and Effective? What We Know

Why It Matters

Broader approval could unlock a sizable market while reshaping preventive health strategies, but safety concerns demand rigorous data before widespread adoption.

Key Takeaways

• FDA panel urges broader testosterone access, calling it preventive‑care opportunity
• TRAVERSE trial shows no increased cardiovascular events in high‑risk men
• High‑dose testosterone linked to three‑fold higher mortality in Danish steroid study
• Women’s testosterone use remains off‑label in U.S., limited to sexual desire treatment
• FDA may accept applications for low‑libido indication, signaling regulatory shift

Pulse Analysis

The FDA’s December expert panel reignited the testosterone debate by positioning the hormone as a cornerstone of preventive health. While traditional guidelines restrict use to men with documented hypogonadism, the panel’s recommendations could expand prescribing to asymptomatic individuals, creating a multibillion‑dollar market opportunity. This shift mirrors broader trends in personalized medicine, where biomarkers such as low testosterone are being explored for risk‑stratification across cardiovascular, metabolic, and cognitive domains. However, the panel’s enthusiasm must be balanced against safety data, especially given the hormone’s controlled‑substance status and its history of misuse in sports and bodybuilding.

Safety evidence has evolved dramatically. Early concerns about prostate cancer and heart attacks prompted FDA warnings, yet the large‑scale TRAVERSE trial—enrolling roughly 5,200 men with confirmed low testosterone and high cardiovascular risk—found no excess of heart attacks, strokes, or mortality compared with placebo. Consequently, the FDA removed the cardiovascular warning in 2023. In contrast, high‑dose testosterone, often conflated with anabolic‑steroid abuse, is associated with a three‑fold increase in mortality, cardiomyopathy, infertility, and neuropsychiatric effects, underscoring the importance of dose‑appropriate prescribing and vigilant monitoring.

Regulatory dynamics are poised for change. The FDA’s recent invitation for applications targeting low libido in men signals a potential loosening of current restrictions, while the agency continues to evaluate the controlled‑substance classification. For women, the landscape remains fragmented; off‑label use of male formulations persists despite limited approvals in only four countries. As the market expands, clinicians, insurers, and policymakers will need robust, large‑scale trials—potentially involving 10,000 older men—to confirm whether routine testosterone testing and treatment can truly prevent disease and justify the anticipated commercial upside.